All News

'Encouraging' Period of Stable Disease Suggested in Direct Injection Vaccine Treatment of Pancreatic Cancer. Research from Rutgers Cancer Institute of New Jersey to be presented at the Pancreatic Cancer-focused meeting held by AACR in New Orleans.

Amid strong lobbying by business groups, support is growing to end the Affordable Care Act's employer mandate, a change that would see millions more Americans buying their health insurance through exchanges.

A new study estimates that it would cost Medicare about $2 billion a year to screen certain current and former heavy smokers for lung cancer.

As part of a contract extension with Tenet Healthcare, Cigna has established a first of its kind quality-based reimbursement agreement.

A CMS ruling would force healthcare providers to enroll in Medicare by June 1, 2015, if they plan to prescribe medications that are paid for by the program. The agency said in a report that changes to Medicare Part D were necessary in order to cut down on inappropriate prescription practices and to improve patient safety.

NICE rejected Celgene's Revlimid again for treating patients with myelodysplastic syndrome, quoting concerns with cost-effectiveness of the drug.

CO-1686 was assigned breakthrough designation by the FDA as monotherapy for the treatment of EGFR-mutant NSCLC patients.

Results presented at the 2014 American Urological Association (AUA) meeting in Florida revealed that Myriad's prostate cancer diagnostic test could predict mortality risk in prostate cancer.

New Health Resources and Services Administration (HRSA) regulations could limit certain hospitals from participating in the 340B drug discount program.

Health and policy experts are pushing for a system that pays doctors a lump sum for medical care or allows them to share in savings, saying it will save millions of dollars over current fee-for-service payments that can lead to fraud and over-use of medications.

Parents in low-income families were less likely to delay asthma care for their children or avoid taking their children to see a doctor is they had lower vs. higher levels of health insurance cost-sharing.

Combining a novel radioimmunotherapy treatment with gemcitabine presented encouraging results in PDAC patients who had undergone metastasis. The data was presented at a AACR special conference currently being held in New Orleans.

GSK/GenMab's monoclonal antibody, Azerra, failed to improve PFS over a rituxan/chemotherapy combination in patients with relapsed/refractory diffuse large B-cell lymphoma.

Few states could claim Obamacare's first enrollment period was smooth-whatever the final numbers-but most will approach their insurance exchanges the same way for the 2015 window. None has asked the Obama administration to take over its marketplace or elected to abandon HealthCare.gov in favor of running its own.

Researchers at Brown University may provide a new early diagnostic test for pancreatic cancer.

Encouraging results from mid-trial analysis have prompted an early halt of the clinical trial for palbociclib and plans to apply for approval.

Orteronel combined with prednisone showed significant PFS but not OS in a double-blind, randomized phase 3 trial.

The CMS on Friday issued its final rule for exchange and insurance market standards for 2015 and beyond, a potpourri of policies that address consumer notices, quality reporting and enrollee satisfaction surveys, the Small Business Health Options Program (SHOP), standards for navigators and other consumer assisters, and policies regarding the premium stabilization programs, among others.

Surgery patients covered by Medicaid arrive at the hospital in worse health, experience more complications, stay longer and cost more than patients with private insurance, a new study has found.

Focus on services' worth to combat soaring healthcare spending.

The overuse of pricey medical technology and medication presents a complex challenge for policymakers, hospitals and doctors trying to reduce costs.

In an era of heavy-duty strategies and tough decisions, one healthcare expert urged providers to consider the accountable care organization (ACO) as part of their future.

A leading Belgium-based company that offers personalized medicine to cancer patients, OncoDNA, has chosen to partner with N-of-One for interpretation of next-generation sequencing data of tumor samples.

BMS announced in a press release the breakthrough designation received by it's PD-1 inhibitor antibody, nivolumab, for treating Hodgkin's lymphoma.

Stage IV NSCLC patients with metastatic SCC showed significantly improved survival when necitumumab, an EGFR-targeted antibody, was combined with gemcitabine and cisplatin (11.5 months), compared to chemotherapy alone (9.9 months).

Every person covered by Medicare would shell out an additional $3 a month if the government agreed to pay to screen certain current and former smokers for lung cancer, a new study estimates.

Using mystery shoppers looking for access to health care, Public Health Seattle & King County has found troubling indications that access to primary-care providers may not be as advertised.

University of Chicago's Comprehensive Cancer Center received $3.9 million from the NCI as the Lead Academic Participating Site for the new NCTN initiative.

States that resisted expanding their Medicaid programs still saw an increase in new enrollees through the end of March.